Johannes Noé

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +16

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Dermatology, Oncology +13

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Tony Mok, D. Ross Camidge, Shirish M. Gadgeel et al. · Annals of Oncology · 2020 · 686 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

D. Ross Camidge, Rafał Dziadziuszko, Solange Peters et al. · Journal of Thoracic Oncology · 2019 · 491 citations · Full text

Medicine, Oncology, Pharmacology +15

Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn et al. · New England Journal of Medicine · 2024 · 382 citations

Medicine, Oncology, Medical Oncology +6